BGLC

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging healthcare platforms, today highlighted its participation in the 2026 China–Malaysia Economic Cooperation Outlook Forum, held on May 21, 2026 at the Mandarin Oriental Hotel in Kuala Lumpur. The forum, held under the theme "Advancing Biotechnology and Healthcare Collaboration towards a China–Malaysia Community with a Shared Future," brought together government representatives, industry leaders, investors, healthcare professionals, and experts from Malaysia and

10-Q - BioNexus Gene Lab Corp (0001737523) (Filer)

10-K - BioNexus Gene Lab Corp (0001737523) (Filer)

NT 10-K - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd ("Fidelion") transaction, Dr. Muthu Meyyappan has been appointed Chief Commercial Officer of Fidelion. Fidelion is a precision diagnostics company focused on advancing next-generation oncology testing technologies, including minimal residual disease (MRD) liquid biopsy assays. Fidelion serves as the international intellectual property and commercialization vehicle for the VitaGuard™ MRD technology developed by Tongshu Gene, supporting commercialization initiatives outside Greater China. BGLC is a strategic investor in Fi

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. ("Chemrex"). As part of this restructuring, Chemrex's board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline Chong, Chief Financial Officer of BioNexus, Director New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private subsidiary of BioNexus and operates un

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

KUALA LUMPUR, Malaysia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a technology-driven precision diagnostics company, today announced the formal commencement of its 2026 Deployment Phase for the VitaGuard™ Minimal Residual Disease (MRD) platform. This phase marks the transition of VitaGuard™ from a technological breakthrough into what the Company believes will be a scalable oncology infrastructure, designed to displace high-cost legacy monitoring systems throughout Southeast Asia. Initial deployments are expected to commence in select Southeast Asian medical hubs during 2026. The Economic Imperative: Shattering the $3,000 Barrier

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

DEF 14A - BioNexus Gene Lab Corp (0001737523) (Filer)

KUALA LUMPUR, Malaysia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BGLC" or the "Company"), a biotechnology company advancing precision diagnostics and gene-based technologies, today announced the formal completion of its strategic transaction with Fidelion Diagnostics Pte. Ltd. ("Fidelion") and Tongshu Biotechnology. With the closing of the agreements, BGLC has become a strategic shareholder in Fidelion Diagnostics and secured exclusive commercial rights for the VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform across Southeast Asia (ASEAN) — positioning the Company for long-term growth as precision oncology adoption accelerates a

SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. ("BGLC" or the "Company"), an emerging provider of precision oncology diagnostics with expanding operations across Southeast Asia, today announced it has entered into a $500,000,000 Equity Purchase Agreement (the "Facility") with ARC Group International Ltd. ("ARC"), a global investment bank and the parent of ARC Group Securities, a FINRA registered broker dealer. The Company believes this facility will provide it with long-term, discretionary access to capital to advance its strategic initiatives, including the commercialization of the VitaGuard™ minimal residual disease (MRD) platform, the addition of contract deve

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

KUALA LUMPUR, Malaysia and SINGAPORE, Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. ("BGLC") today announced that it has executed an Exclusive Intellectual Property License Agreement for Southeast Asia with Fidelion Diagnostics Pte. Ltd. ("Fidelion") for the VitaGuard™ minimal residual disease ("MRD") liquid biopsy platform. The license is a key condition precedent to the closing of the previously announced Share Subscription and Shareholders' Agreement among BGLC, Fidelion and Tongshu Gene, under which BGLC will become a strategic shareholder in Fidelion and, in return, Fidelion will hold a minority stake in BGLC. Exclusive, Perpetual Rights in Southeast Asia Under the lice

10-Q - BioNexus Gene Lab Corp (0001737523) (Filer)

PRE 14A - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

KUALA LUMPUR, Malaysia and SINGAPORE, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. ("BGLC, ("BGLC," NASDAQ:BGLC) today announced it has entered into definitive agreements with Fidelion Diagnostics Pte. Ltd. ("Fidelion") and Tongshu Biotechnology (Hong Kong) Co., Limited ("Tongshu"), among other parties, to commercialize VitaGuard™, a high-fidelity, tumor-naïve liquid-biopsy platform for minimal residual disease (MRD). The parties executed a Share Subscription and Shareholders' Agreement aligning ownership and governance around a rapid Southeast Asia rollout. The collaboration is intended to support the development and planned commercialization of MRD testing in Southeast Asi

KUALA LUMPUR, Malaysia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a biotechnology company advancing precision diagnostics and gene-based technologies across Asia and the U.S., today announced that it has filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission ("SEC") to register up to $100 million of securities that may be offered from time to time.Under this shelf, the Company has entered into an Equity Distribution Agreement with Maxim Group LLC, pursuant to which it may, subject to the effectiveness of the registration statement, offer and sell up to $20 million of its common stock through a

S-3 - BioNexus Gene Lab Corp (0001737523) (Filer)